JUN 16, 2021 7:25 AM PDT

New drug attacks pancreatic tumors with mutant KRAS addiction

Pancreatic cancer is notoriously difficult to detect in early stages, which is why it is associated with a low survival rate. Now a study published in Clinical Cancer Research identifies a drug that is capable of derailing pancreatic tumors that are dependent on the mutant KRAS gene.

Approximately 90% of pancreatic cancers harbor mutant KRAS and some tumors have even been shown in previous studies to be unable to survive without the gene – what’s called a mutant KRAS addiction. Watch the video below to learn more about the KRAS gene and how it causes cancer.

In researching mutant KRAS addition, Said Sebti, Ph.D., who is associate director for basic research at VCU Massey Cancer Center, discovered a drug that can kill pancreatic tumors with mutant KRAS addiction. "We discovered a link between hyperactivation of the CDK protein and mutant KRAS addiction, and we exploited this link preclinically to counter mutant KRAS-driven pancreatic cancer, warranting clinical investigation in patients afflicted with this deadly disease," said Sebti. "Our findings are highly significant as they revealed a new avenue to combat an aggressive form of pancreatic cancer with very poor prognosis due mainly to its resistance to conventional therapies."

"Using three entirely different approaches, the same conclusion presented itself clearly to us: pancreatic cancer patients whose tumors are addicted to mutant KRAS could benefit greatly from treatment with the CDK inhibitor AT7519," Sebti adds.

Further tests showed that AT7519 was also able to suppress the growth of xenograft cells from five mutant KRAS pancreatic cancer patients who had not experienced success with chemotherapy and/or radiation. Next, the researchers hope to test out AT7519 in clinical trials targeting pancreatic cancer.

"If our findings are correct and translate in humans, then we should be able to see a positive response in pancreatic cancer patients whose tumors are addicted to mutant KRAS," Sebti said.

Sources: Clinical Cancer Research, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
MAY 05, 2021
Cancer
Developing Therapies to Combat Drug-Resistant Cell States
MAY 05, 2021
Developing Therapies to Combat Drug-Resistant Cell States
Drug resistant tumors present challenges in cancer treatment A significant challenge in the treatment of cancers is the ...
MAY 13, 2021
Cancer
Ovarian cancer screening doesn't save lives, reports new study
MAY 13, 2021
Ovarian cancer screening doesn't save lives, reports new study
New research published in the journal The Lancet highlights the eagerly awaited results of the UK Collaborative Trial of ...
MAY 28, 2021
Genetics & Genomics
Some Biofilms Seem to Activate Cancer Genes
MAY 28, 2021
Some Biofilms Seem to Activate Cancer Genes
New research assessed bacterial and fungal biofilms, tenacious microbial communities that are tougher than small groups ...
JUN 22, 2021
Cancer
Evaluating adverse effects of induction therapy for neuroblastoma
JUN 22, 2021
Evaluating adverse effects of induction therapy for neuroblastoma
A study published in the Journal of Clinical Oncology reports an evaluation of the chemotherapy treatment given to child ...
JUN 26, 2021
Cancer
Immunotherapy Drug Shows Promise for Obese Patients with Breast Cancer
JUN 26, 2021
Immunotherapy Drug Shows Promise for Obese Patients with Breast Cancer
Research shows that obese patients with cancers including ovarian and melanoma may respond better to a certain kind of i ...
JUL 13, 2021
Clinical & Molecular DX
Friend or Foe? New Cancer-Tracking Pen Guides Surgeons.
JUL 13, 2021
Friend or Foe? New Cancer-Tracking Pen Guides Surgeons.
Researchers have developed the first diagnostic “pen” that acts as a guide for surgeons, helping them distin ...
Loading Comments...